Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: A systematic review and meta-analysis

Sheng Li, Xian-Tao Zeng, Xiao-Lan Ruan, Xing-Huan Wang, Yi Guo, Zhong-Hua Yang, Sheng Li, Xian-Tao Zeng, Xiao-Lan Ruan, Xing-Huan Wang, Yi Guo, Zhong-Hua Yang

Abstract

The aim of this study was to evaluate the recurrence rate of simultaneous transurethral resection of bladder cancer and prostate (TURBT+TURP) in the treatment of non-muscle invasive bladder cancer (NMIBC) with benign prostatic hyperplasia (BPH). We searched PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and the ISI Web of Knowledge databases from their establishment until March 2012, to collect all the original studies on TURBT+TURP vs. TURBT alone in the treatment of NMIBC with BPH. After screening the literature, methodological quality assessment and data extraction was conducted independently by two reviewers and meta-analysis was performed using the RevMan 5.1 software. The quality of data was assessed using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. Eight studies, including seven non-randomized concurrent controlled trials (NRCCTs) and one randomized controlled trial (RCT), involving a total of 1,372 patients met the criteria. Meta-analyses of NRCCTs showed that in the TURBT+TURP group, overall recurrence rates were lower [odds ratio (OR), 0.76; 95% confidence interval (CI), 0.60-0.96; P=0.02] and the difference was statistically significant. The postoperative recurrence rate in the prostatic fossa/bladder neck (OR, 0.96; 95% CI, 0.64-1.45; P=0.86) and bladder tumor progression rates (OR, 0.96; 95% CI, 0.49-1.87; P=0.91) were similar between the TURBT+TURP and TURBT groups, but the difference was not significant. According to the GRADE approach, the level of evidence was moderate or low. Only one RCT demonstrated that overall postoperative tumor recurrence rates, recurrence rates at prostate fossa/bladder neck and bladder tumor progression rates between simultaneous groups and control groups were almost equal. There was no significant difference (P>0.05), and the level of evidence was moderate. For patients with NMIBC and BPH, simultaneous resection did not increase the overall recurrence rate of bladder tumors, it also did not cause metastasis and tumor progression, but it may reduce the recurrence rate. However, due to the low quality of investigations included in the present study, careful selection was necessary, and more large-scale and high-quality randomized controlled trials are also required for further confirmation.

Figures

Figure 1
Figure 1
Flowchart for selecting RCTs and NRCCTs for the meta-analysis. RCT, randomized controlled trial; NRCCT, non-randomized concurrent controlled trial.
Figure 2
Figure 2
Overall tumour recurrence rates of pooled NRCCTs. NRCCT, non-randomized concurrent controlled trial; CI, confidence interval.
Figure 3
Figure 3
Recurrence rate at the prostatic urethra and/or bladder neck of pooled NRCCTs. NRCCT, non-randomized concurrent controlled trial; CI, confidence interval.
Figure 4
Figure 4
Tumor progression of pooled NRCCTs. NRCCT, non-randomized concurrent controlled trial; CI, confidence interval.

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
    1. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59:997–1008.
    1. Rowhrborm CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, editors. Campbell's Urology. W. B. Saunders Company; Philadelphia, PA: 2002. pp. 1297–1330.
    1. Kiefer JH. Bladder tumor recurrence in the urethra: a warning. J Urol. 1953;69:652–656.
    1. Hinman F., Jr Recurrence of bladder tumors by surgical implantation. J Urol. 1956;75:695–696.
    1. Greene LF, Yalowitz PA. The advisability of concomitant transurethral excision of vesical neoplasm and prostatic hyperplasia. J Urol. 1972;107:445–447.
    1. Kouriefs C, Loizides S, Mufti G. Simultaneous transurethral resection of bladder tumour and prostate: is it safe? Urol Int. 2008;81:125–128.
    1. Luo SJ, Lin YJ, Zhang WL. Does simultaneous transurethral resection of bladder tumor and prostate affect the recurrence of bladder tumor? A meta-analysis. J Endourol. 2011;25:291–296.
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated Macch 2011) The Cochrane Collaboration. 2011 Available at .
    1. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712–716.
    1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
    1. GRADEpro. [Computer program]. Version 3.6 for Windows. Brozek J, Oxman A, Schünemann H, 2011.
    1. Singh W, Sinha RJ, Sankhwar SNS. Outcome of simultaneous transurethral resection of bladder tumor and transurethral resection of the prostate in comparison with the procedures in two separate sittings in patients with bladder tumor and urodynamically proven bladder outflow obstruction. J Endourol. 2009;23:2007–2011.
    1. Laor E, Grabstald H, Whitmore WF. The influence of simultaneous resection of bladder tumors and prostate on the occurrence of prostatic urethral tumors. J Urol. 1981;126:171–175.
    1. Vicente J, Chéchile G, Pons R, Méndez G. Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate. Eur Urol. 1988;15:40–42.
    1. Ugurlu O, Gonulalan U, Adsan O, Kosan M, Oztekin V, Cetinkaya M. Effects of simultaneous transurethral resection of prostate and solitary bladder tumors smaller than 3 cm on oncologic results. Urology. 2007;70:55–59.
    1. Kim S, Park S, Ahn H. Oncologic results of simultaneous transurethral resection of superficial bladder cancer and benign prostatic hyperplasia. Urology. 2009;74:S144.
    1. Ham WS, Kim WT, Jeon HJ, Lee DH, Choi YD. Long-term outcome of simultaneous transurethral resection of bladder tumor and prostate in patients with nonmuscle invasive bladder tumor and bladder outlet obstruction. J Urol. 2009;181:1594–1599.
    1. Jaidane M, Bouicha T, Slama A, et al. Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate: a comparative retrospective study. Urology. 2010;75:1392–1395.
    1. Mommsen S, Sell A. Prostatic hypertrophy and venereal disease as possible risk factors in the development of bladder cancer. Urol Res. 1983;11:49–52.
    1. Fellows GJ. The association between vesical carcinoma and urinary obstruction. Eur Urol. 1978;4:187–188.
    1. Melicow MM, Uson AC, Lipton R. beta-Glucuronidase activity in the urine of patients with bladder cancer and other conditions. J Urol. 1961;86:89–94.
    1. Karaguzhin SG, Merinov DS, Martov AG. One-stage transurethral resection of the urinary bladder and the prostate in patients with superficial cancer of the urinary bladder combined with benign prostatic hyperplasia. Urologiia. 2005:17–21. (In Russian)
    1. Schulz KF, Moher D, Altman DG. CONSORT 2010 comments. Lancet. 2010;376:1222–1223.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel